- A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)
Pedro Barata et al, 2018, Invest New Drugs CrossRef - Therapeutic Targeting of the IGF Axis.
Eliot Osher et al, 2019, Cells CrossRef - In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state
Alexander Aliper et al, 2016, Aging CrossRef - Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
Xia Gan et al, 2022, Pharmaceuticals CrossRef - Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine
Syuan-Ling Lin et al, 2022, IJMS CrossRef - Small-Molecule Protein Tyrosine Kinase Inhibitors for the Treatment of Metastatic Prostate Cancer
Gary E Gallick et al, 2012, Future Med. Chem. CrossRef - null
Sandipan Das et al, 2024 CrossRef